oral KRAS(G12C) inhibitor

oral efficacy in xenograft model

from literature starting point and SBDD

J. Med. Chem.

AstraZeneca, Cambridge, UK

AZD4625 chemical structure, oral KRAS(G12C) inhibitor - AstraZeneca, Cambridge, UK

Context. AZD4625 (AstraZeneca) is an oral inhibitor of KRASG12C being developed for the treatment of advanced solid malignancies. As indicated for JDQ443, the KRASG12C mutation presents the perfect ÔÇťAchilles…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: